Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users-Reference-Cited by-同舟云学术

Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users

Published:2019-06-07 Issue:6 Volume:2 Page:e195345
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Chanfreau-Coffinier Catherine¹,Hull Leland E.²³,Lynch Julie A.¹³⁴,DuVall Scott L.¹⁵,Damrauer Scott M.⁶⁷,Cunningham Francesca E.⁸,Voight Benjamin F.⁶,Matheny Michael E.⁹¹⁰,Oslin David W.⁶⁷,Icardi Michael S.¹¹¹²¹³,Tuteja Sony⁶⁷

Affiliation:

1. US Department of Veterans Affairs, VA Informatics and Computing Infrastructure, Salt Lake City Health Care System, Salt Lake City, Utah

2. Center for Healthcare Organization and Implementation Research, US Department of Veterans Affairs, Boston Healthcare System, Boston, Massachusetts

3. US Department of Veterans Affairs, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, Massachusetts

4. College of Nursing and Health Sciences, University of Massachusetts, Boston

5. Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City

6. Perelman School of Medicine, University of Pennsylvania, Philadelphia

7. Corporal Michael Crescenz Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania

8. US Department of Veterans Affairs Center for Medication Safety, Pharmacy Benefits Management Services, Hines, Illinois

9. Geriatrics Research Education and Clinical Care Center, US Department of Veterans Affairs Tennessee Valley Healthcare System, Nashville

10. Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee

11. US Department of Veterans Affairs Iowa City Healthcare System, Iowa City, Iowa

12. US Department of Veterans Affairs National Office of Pathology and Laboratory Medicine, Iowa City, Iowa

13. Carver College of Medicine, University of Iowa, Iowa City

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

http:///jamanetworkopen/article-pdf/2/6/e195345/17635264/chanfreaucoffinier_2019_oi_190219.pdf

Reference45 articles.

1. Pharmacogenomics knowledge for personalized medicine.;Whirl-Carrillo;Clin Pharmacol Ther,2012

2. Pharmacogenomics in the clinic.;Relling;Nature,2015

3. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing.;Van Driest;Clin Pharmacol Ther,2014

4. Genetic variation among 82 pharmacogenes: the PGRNseq data from the eMERGE network.;Bush;Clin Pharmacol Ther,2016

5. Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade.;Ji;J Mol Diagn,2016

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Should secondary pharmacogenomic variants be actively screened and reported when diagnostic genome-wide sequencing is performed in a child?;Genetics in Medicine;2024-02

2. Ontology anchored decision support tools: A focus on pharmacogenomics;Comprehensive Precision Medicine;2024

3. Trends and implementation of preemptive pharmacogenomic testing;Comprehensive Precision Medicine;2024

4. Mining local exome and HLA data to characterize pharmacogenetic variants in Saudi Arabia;Human Genetics;2023-12-30

5. Implementing preemptive, multigene, pharmacogenomic testing in the inpatient setting: Preliminary results from a small, rural facility;JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY;2023-12-28